Drug Trial Radar · NCT06368440
A Study to Investigate the Safety and Pharmacokinetics of AZD6793 in Healthy Japanese and Chinese Participants
Last checked: Nov 19, 2026Latest source record: Oct 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
39
Actual
Start
May 15, 2024
Primary completion
Dec 23, 2024
Study completion Dec 23, 2024
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Apr 16, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The main purpose of this study is to assess the safety, tolerability and pharmacokinetics (PK) of oral AZD6793 in healthy Japanese and Chinese participants.
Conditions
- Healthy Participants
Interventions
AZD6793Drug
Participants will receive AZD6793 single dose as oral suspension.
AZD6793Drug
Participants will receive AZD6793 multiple doses daily as oral suspension.
PlaceboDrug
Participants will receive matching doses of placebo as oral suspension.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1 (SAD): Number of Participants with Adverse EventsTime frame: From Day 1 up to Follow up visit (Day 7±1)
- Part 2 (MAD): Number of Participants with Adverse EventsTime frame: From Day 1 up to Follow up visit (Day 14±1)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Research Site
Glendale, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.